MeiraGTx Holdings plc Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (8 lists). Names and jurisdictions are as filed.
- 2026-03-30: Subsidiary Legal Name of Subsidiary; Jurisdiction Jurisdiction of Organization.
- 2026-03-30: Subsidiary BRI-Alzan, Inc.; Jurisdiction Delaware.
- 2026-03-30: Subsidiary MeiraGTx B.V.; Jurisdiction Netherlands.
- 2026-03-30: Subsidiary MeiraGTx Netherlands B.V.; Jurisdiction Netherlands.
| Annual report filed | Subsidiary | Jurisdiction |
|---|---|---|
| 2026-03-30 | Legal Name of Subsidiary | Jurisdiction of Organization |
| 2026-03-30 | BRI-Alzan, Inc. | Delaware |
| 2026-03-30 | MeiraGTx B.V. | Netherlands |
| 2026-03-30 | MeiraGTx Netherlands B.V. | Netherlands |
| 2026-03-30 | MeiraGTx Limited | England and Wales |
| 2026-03-30 | MeiraGTx, LLC | Delaware |
| 2026-03-30 | MeiraGTx UK Limited | England and Wales |
| 2026-03-30 | MeiraGTx UK II Limited | England and Wales |
| 2026-03-30 | MeiraGTx Ireland DAC | Ireland |
| 2026-03-30 | MeiraGTx Neurosciences, Inc. | Delaware |
| 2026-03-30 | MeiraGTx Bio Inc. | Delaware |
| 2026-03-30 | MeiraGTx Belgium | Belgium |
| 2026-03-30 | MeiraGTx Therapeutics, Inc. | Delaware |
| 2026-03-30 | MeiraGTx Neuro I, LLC | Delaware |
| 2026-03-30 | MeiraGTx Neuro II, LLC | Delaware |
| 2026-03-30 | MeiraGTx Manufacturing Limited | England and Wales |
| 2026-03-30 | MeiraGTx Ocular UK Limited | England and Wales |
| 2026-03-30 | MeiraGTx Gene Regulation Limited | England and Wales |
| 2026-03-30 | MeiraGTx Neuro UK Limited | England and Wales |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |